32例替吉奥联合多西他赛治疗复发转移乳腺癌临床观察  

The efficacy and toxicity of docetaxel combined wifh compound tegafur capsule on anthracycline-refractory recurrent metastatic breast cancel

作　　者：庄民[1] 李艳[1] 卞宝祥[1] 宋子琰[1] 郑义同[1] 

机构地区：[1]江苏省连云港市第一人民医院肿瘤内科,222002

出　　处：《中国老年保健医学》2014年第2期50-52,共3页Chinese Journal of Geriatric Care

摘　　要：目的研究替吉奥(维康达)联合多西他赛治疗蒽环类药物治疗失败复发转移性乳腺癌的疗效和安全性。方法复发转移性乳腺癌患者32例,多西他赛75mg/m2,静脉滴注,d1;替吉奥40mg/m2,2次/日,d1-14,21天为一个周期。治疗2个周期评价疗效及安全性。结果 32例患者均可评价疗效,3例(9.4%)CR,14例(43.7%)PR,8例(25%)SD,7例(21.9%)PD。客观有效率(CR+PR)为53.1%,临床获益率(CR+PR+SD)为78.1%。不良反应为骨髓抑制、胃肠道反应等,均可耐受。结论替吉奥联合多西他赛是治疗蒽环类药物治疗失败复发转移性乳腺癌的有效方案,其不良反应能够耐受。Objective To investigate the efficacy and toxicity of docetaxel combined wifh compound tegafur capsule（ S-1 ） on anthracycline-refractory recurrent metastatic breast cancel （ ARMBC ）. Methods Thirty-two ARMBC patients were given intravenous 75mg/m2 doeetaxel at day 1 ,and oral 40mg/m2 S-1 twice every day at day 1 to 1 4. Twenty-one days was one cycle and each patient received at least two cycles. Results Efficacy and toxcities could be evaluated in 32 patients, and there were 3 cases of complete remission （CR） , 14 cases of partial remission （PR） , 8 cases of stability （ SD ） and 7 cases of disease-progression （PD）. The objective response rate（ CR ＋ PR） was 53. 1% and disease control rate（ CR ＋ PR ＋ SD） was 78.1%. The main toxicity was myelosuppression and gastrointestinal reactions, which were mainly Ⅰ - Ⅱ degree, and could be welholerated. Conclusion Good clinical efficacy were achieved in the therapy ofmetastatic breast cancer with docetaxel and S-1 combination regimen and toxic reactions are tolerable.

关 键 词：替吉奥 多西他赛 复发转移性乳腺癌 化疗 

分 类 号：R737.9[医药卫生—肿瘤]